Kenneth Hillan - Achaogen President CEO, Chief Medical Officer, Director
CEO
Dr. Kenneth J. Hillan M.B. Ch.B. is no longer President, President RD and Director of the Company, effective October 15, 2018. He has served on the Board since October 2011. Dr. Hillan served as the Companys Chief Medical Officer from April 2011 until July 2014, served as the Companys President from October 2011 to February 2017 and has served as the Companys Chief Executive Officer since October 2011. Prior to joining Achaogen, from 1994 to April 2011, Dr. Hillan served at Genentech. Dr. Hillan was responsible for numerous successful drug approvals and led the medical and scientific strategies for Genentechs Immunology, Tissue Growth and Repair drug portfolio. For Genentech, he served in a number of key leadership positions in research and development, including Senior Vice President Clinical Development, Inflammation, Vice President Immunology, Tissue Growth and Repair, Vice President Development Sciences and Vice President Research Operations and Pathology. Dr. Hillan also previously served as Senior Vice President and head of Clinical Development and Product Development Strategy in AsiaPacific for F. HoffmannLa Roche AG in Shanghai, China. Dr. Hillan served on the board of directors of Relypsa, Inc., a publicly traded biotechnology company, from June 2014 to September 2016 when it merged with Galenica AG. Dr. Hillan holds an M.B. Ch.B. degree from the Faculty of Medicine at the University of Glasgow, U.K. Dr. Hillan is a Fellow of the Royal College of Surgeons, and a Fellow of the Royal College of Pathologists. Dr. Hillan has authored dozens of scientific publications and is a named inventor on almost 50 issued patents. since 2018.
| Age | 56 |
| Tenure | 6 years |
| Phone | 650 800-3636 |
| Web | www.achaogen.com |
Achaogen Management Efficiency
Achaogen's management efficiency ratios could be used to measure how well Achaogen manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 49.78 M in liabilities with Debt to Equity (D/E) ratio of 99.9, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Achaogen has a current ratio of 0.76, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Achaogen until it has trouble settling it off, either with new capital or with free cash flow. So, Achaogen's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Achaogen sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Achaogen to invest in growth at high rates of return. When we think about Achaogen's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 9 records | CEO Age | ||
| Sue Nabi | Coty Inc | 56 | |
| Yoshifumi Nakaya | Amkor Technology | 51 | |
| Pierre Laubies | Coty Inc | 61 | |
| Fabrizio Freda | Estee Lauder Companies | 67 | |
| Jacqueline Ardrey | Vera Bradley | 54 | |
| Stephen Kelley | Amkor Technology | 55 | |
| Joy Fan | Estee Lauder Companies | N/A | |
| Robert Wallstrom | Vera Bradley | 58 | |
| Thomas Lingelbach | Valneva SE ADR | 61 | |
Management Performance
| Return On Equity | -4.0E-4 | |||
| Return On Asset | -2.0E-4 |
Achaogen Leadership Team
Elected by the shareholders, the Achaogen's board of directors comprises two types of representatives: Achaogen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Achaogen. The board's role is to monitor Achaogen's management team and ensure that shareholders' interests are well served. Achaogen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Achaogen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Janet Dorling, Chief Commercial Officer | ||
| Paal Johnsen, Executive Vice President - Investment Director | ||
| Christopher Walsh, Independent Director | ||
| Ian Friedland, Chief Medical Officer | ||
| Liz Bhatt, COO | ||
| Gary Loeb, General Counsel | ||
| Sarah Ryan, Director | ||
| Leif Borge, CFO | ||
| Zeryn Sarpangal, Principal Financial Officer, Principal Accounting Officer and VP of HR and Corporate Affairs | ||
| Halley Gilbert, Director | ||
| John Smither, Independent Director | ||
| Lee Swem, Senior Vice President Chief Scientific Officer | ||
| Stian Sjolund, Director, Employee Representative | ||
| Blake Wise, COO | ||
| Gregory Stea, Director | ||
| Tobin Schilke, CFO, Principal Financial Officer and Principal Accounting Officer | ||
| Kent Lieginger, Director | ||
| Elizabeth Bhatt, COO | ||
| Asle Halvorsen, Director, Employee Representative | ||
| Kristian Rokke, Chairman of the Board | ||
| Alan Colowick, Director | ||
| John Doyle, Director | ||
| Oyvind Eriksen, Director | ||
| Kenneth Hillan, President CEO, Chief Medical Officer, Director | ||
| Lone Schroder, Deputy Chairman of the Board | ||
| Henning Jensen, Director, Employee Representative | ||
| Michael Fischbach, Director | ||
| Karen Bernstein, Independent Director | ||
| Karl Kjelstad, CEO | ||
| Bryan Roberts, Chairman of the Board | ||
| Kathryn Baker, Director |
Achaogen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Achaogen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -4.0E-4 | |||
| Return On Asset | -2.0E-4 | |||
| Profit Margin | (0.0001) % | |||
| Operating Margin | (108.76) % | |||
| Current Valuation | 25.7 M | |||
| Shares Outstanding | 63.88 M | |||
| Shares Owned By Insiders | 7.69 % | |||
| Shares Owned By Institutions | 46.66 % | |||
| Number Of Shares Shorted | 7.52 M | |||
| Price To Earning | (4.37) X |
Pair Trading with Achaogen
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Achaogen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Achaogen will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Microsoft could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Microsoft when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Microsoft - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Microsoft to buy it.
The correlation of Microsoft is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Microsoft moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Microsoft moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Microsoft can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the Achaogen information on this page should be used as a complementary analysis to other Achaogen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Other Consideration for investing in Achaogen Stock
If you are still planning to invest in Achaogen check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Achaogen's history and understand the potential risks before investing.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |